arrow
Y

Yasuhide Yamada

Department of Research Management
H指数:62
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

PD-L1表达和未经免疫检查点抑制剂治疗的不可切除/复发性胃癌一线治疗后的生存情况:JCOG1013A1研究

2026-09-040
OAAI
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study

一种基于外泌体的液体活检技术用于早期结直肠癌的检测:ENCODER多中心研究

2025-12-090
OAAI
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
2021-09-017
OA
The efficacy and safety of FOLFIRI plus BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial
2019-10-010
OAAI
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

多西他赛联合顺铂和S-1与顺铂和S-1治疗晚期胃癌 (JCOG1013): 一项开放标签,3期,随机对照试验

2019-07-0196
PREAI
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
2018-03-0163
OAAI
A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)
2018-03-014
PREAI